A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,306

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccinesPreprint

Addetia, A., Schäfer, A., Sprouse, K. R., Valdez, A., Taylor, A., Navarro, M.-J., Brown, J. T., Leaf, E. M., Miranda, M. C., Walls, A. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652904 · Cited by 4

Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination

Sanada, T., Honda, T., & Kohara, M. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.047 · Cited by 4

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

Shinde, V., Koen, A. L., Hoosain, Z., Archary, M., Bhorat, Q. E., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2425147 · Cited by 3

Broad neutralizing antibody response of a monomeric spike–based SARS-CoV-2 bivalent vaccine against diverse variants

Wang, S., Sun, H., Wang, Y., Wang, Z., Yuan, L., Guo, H., Gao, J., Lan, M., Wu, Y., Shang, H., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2503254122 · Cited by 4

Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics

Teplensky, M. H., Bourgeois, J. N., Kudruk, S., Petrosko, S. H., & Mirkin, C. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409553122 · Cited by 3

Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling

Zhang, C. J., Fan, J., Guo, Y., Xiao, F., Chao, J., & Yang, D. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.2621334 · Cited by 3

First booster dose uptake of COVID-19 vaccine and disease-related factors in chronic obstructive pulmonary disease—a cross-sectional survey in Hungary

Fekete, M., Horváth, A. Z., Sánta, B., Tomisa, G., Szöllösi, G. J., & Varga, J. T. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1256 · Cited by 3

Emergence of SARS-CoV-2 serotype(s): Is it a matter of time?

Júnior, J. V. J. S., Durães‐Carvalho, R., de Souza, J. R., Janini, L. M., Weiblen, R., & Flores, E. F. (2023) · Virology · doi:10.1016/j.virol.2023.04.014 · Cited by 3

Relative effectiveness and durability of booster doses of SARS-CoV-2 vaccines: A systematic review and meta-analysis

Liu, D., Jiang, Y., Wang, S., Li, F.-X., Lin, T.-F., Li, B., Zhao, Z.-Y., Yun, Q., Peng, N., Cai, J., et al. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100051 · Cited by 2

New insights into three trajectories of omicron-related all-cause death reduced by COVID-19 booster vaccination

Yeh, Y., Lin, T.-Y., Yao, Y.-C., Hsu, C.-Y., Yen, A. M., Chen, S. L., & Chen, T. H.-H. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.006 · Cited by 3

Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern

Файзулоев, Е. Б., Gracheva, A. V., Korchevaya, E. R., Ammour, Y. I., Smirnova, D. I., Khokhlova, D. M., Drokov, A. O., Pankratov, A. A., Trunova, G. V., Андреевна, Х. В., et al. (2024) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-496 · Cited by 3

Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2

Lee, B., Bae, G. E., Jeong, I. H., Kim, J., Kwon, M., Kim, J., Kim, B., Lee, J.-W., Nam, J.-H., Huh, H. J., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae014 · Cited by 3

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol

Campos, G. R. F., Almeida, N. B. F., Filgueiras, P. S., Corsini, C. A., Gomes, S. V. C., de Miranda, D. A. P., de Assis, J. V., Silva, T. B. D. S., Alves, P. A., Fernandes, G. D. R., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1371695 · Cited by 3

A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines

Bausch-Jurken, M. T., Dawson, R. S., Ceddia, F., Urdaneta, V., Marks, M. A., & Doi, Y. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2402955 · Cited by 3

Immune histories and natural infection protection during the omicron era

Chemaitelly, H. S., Ayoub, H. H., Bobrovitz, N., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00974-9 · Cited by 3

Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once‐boosted BA.1/2 convalescents and twice‐boosted COVID‐19‐naïve individuals

Kang, C. K., Kim, M., Park, S., Kim, Y., Lee, C. M., Choe, P. G., Park, W. B., Kim, N. J., Kim, M., Lee, S., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28558 · Cited by 3

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters

Berry, C., Pavot, V., Anosova, N. G., Kishko, M., Li, L., Tibbitts, T., Raillard, A., Gautheron, S., Cummings, S., Bangari, D. S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00302-z · Cited by 4

Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review

Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 2

The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics

Yap, J., Kayda, I., Asamoah-Boaheng, M., Haig, S., Kirkham, T. L., Cheskes, S., Demers, P. A., Goldfarb, D. A., & Grunau, B. E. (2023) · Access Microbiology · doi:10.1099/acmi.0.000725.v3 · Cited by 3

Current Insights into Covid-19 Vaccination

Sim, T. C. (2023) · Journal of Medicine University of Santo Tomas · doi:10.35460/2546-1621.2023-0077 · Cited by 3

Live‐virus serum neutralization after bivalent SARS‐CoV‐2 mRNA vaccination in hemodialysis patients

Benning, L., Bartenschlager, M., Kim, H.-Y., Kälble, F., Nußhag, C., Buylaert, M., Reichel, P., Schaier, M., Morath, C. P., Zeier, M., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29303 · Cited by 3

Omicron breakthrough infections after triple‐dose inactivated COVID ‐19 vaccination: A comprehensive analysis of antibody and T‐cell responses

Xiang, T., Quan, X., Jia, H., Wang, H., Liang, B., Li, S., Wang, X., Li, H., Feng, X., Fan, L., et al. (2024) · Immunology · doi:10.1111/imm.13764 · Cited by 3

Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development

Jearanaiwitayakul, T., Sunintaboon, P., Kittiayuwat, A., Limthongkul, J., Wathanaphol, J., Janhirun, Y., Lerdsamran, H., Wiriyarat, W., & Ubol, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.079 · Cited by 3

Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines

Funakoshi, Y., Yakushijin, K., Ohji, G., Matsutani, T., Doi, K., Sakai, H., Sasaki, T., Kusakabe, T., Matsumoto, S., Saito, Y., et al. (2024) · eJHaem · doi:10.1002/jha2.932 · Cited by 3

Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study

Amstutz, A., Chammartin, F., Audigé, A., Eichenberger, A. L., Braun, D. L., Amico, P., Stoeckle, M. P., Hasse, B. K., Papadimitriou‐Olivgeris, M., Manuel, O., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae291 · Cited by 4

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial

Zhou, H., Zheng, H., Peng, Y., Su, Y., Yu, X., Wang, W., Li, S., Ding, Y., Jiao, S., Wang, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407826 · Cited by 3

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial

Griffin, D. W. J., Dymock, M., Wong, G., Morrissey, C. O., Lewin, S. R., Cheng, A. C., Howard, K., Marsh, J. A., Subbarao, K., Hagenauer, M., et al. (2024) · Trials · doi:10.1186/s13063-024-08315-2 · Cited by 3

Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs

Huo, H., Wang, J., Li, C., Xiao, S., Wang, H., Ge, J., Zhong, G., Wen, Z., Wang, C., Lang, Q., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1468775 · Cited by 4

Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant

Parua, P., Ghosh, S., Jana, K., Seth, A., Debnath, B., Rout, S. K., Sarangi, M. K., Dash, R., Halder, J., Rajwar, T. K., et al. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128334441241108050528 · Cited by 3

Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial

Marc, G. P., Coria, L. M., Ceballos, A., Rodriguez, J. M., Lombardo, M., Bruno, L. A., Córdoba, F. P., Cassero, C. G. F., Salvatori, M., Medrano, M. R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127045 · Cited by 3

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy

Selim, R., Wellens, J., Brann, S., Marlow, L., Adams, A. T., & Satsangi, J. J. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00302-8 · Cited by 3

Factors Influencing Parent and Guardian Decisions on Vaccinating Their Children Against SARS-CoV-2: A Qualitative Study

Nickerson, A., Gutierrez-Mock, L., Buback, L., Welty, S., Anicete, L. M., Sánchez, S., Enanoria, W. T. A., & Reid, M. (2023) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580231159742 · Cited by 3

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?

Jin, P., & Zhu, F. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100623 · Cited by 3

Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant‐infected adults: A real‐world cohort study

Peng, D., Gao, Y., Liu, Z., Zheng, J., & Liu, Y. (2023) · The Clinical Respiratory Journal · doi:10.1111/crj.13694 · Cited by 3

Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 boosterPreprint

Wagenhäuser, I., Reusch, J., Gabel, A., Krone, L. B., Kurzai, O., Petri, N., & Krone, M. (2022) · medRxiv · doi:10.1101/2022.11.07.22281982 · Cited by 3

Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in EnglandPreprint

Kirsebom, F. C. M., Andrews, N. J., Stowe, J., Ramsay, M. E., & Bernal, J. L. (2023) · medRxiv · doi:10.1101/2023.03.31.23288018 · Cited by 3

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenPreprint

Dixit, A., Bennett, R., Ali, K., Griffin, C., Clifford, R. A., Turner, M. A., Poston, R., Hautzinger, K., Yeakey, A. M., Girard, B., et al. (2023) · medRxiv · doi:10.1101/2023.06.23.23291767 · Cited by 3

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccinesPreprint

Lee, J., Stewart, C., Schaefer, A., Leaf, E. M., Park, Y., Asarnow, D. E., Powers, J. M., Treichel, C., Corti, D., Baric, R. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571160 · Cited by 3

Traditional and Social Media Usage Associated With COVID-19 Vaccine Uptake in Sapporo, Japan

Sunohara, S., Asakura, T., Kimura, T., Saijo, M., & Tamakoshi, A. (2024) · Asia Pacific Journal of Public Health · doi:10.1177/10105395241240952 · Cited by 2

Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination

Hiranburana, N., Thippamom, N., Avihingsanon, A., Wacharapluesadee, S., Ubolyam, S., Kerr, S. J., Tan, C. W., Wang, L., & Putcharoen, O. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317940 · Cited by 2

XBB.1.5 RBD-Based Bivalent Vaccines Induced Antibody Responses Against SARS-CoV-2 Variants in Mice

Liu, J., Wang, T., Ren, H., Liu, R., Wang, Q., Wu, J., & Liu, B. (2025) · Vaccines · doi:10.3390/vaccines13050543 · Cited by 2

Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity

Kronsteiner, B., Govender, M., Liu, C., Dijokaite-Guraliuc, A., Ali, M., Hill, J. W., Zewdie, M., Cross, A., Austin, J. A., Watts, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-28310-0 · Cited by 2

Risk of spontaneous abortion after mRNA COVID-19 vaccination received just prior to or during pregnancy: Complete data from CDC COVID-19 vaccine pregnancy registry

Madni, S. A., Olson, C. K., Zauche, L. H., Machefsky, A. M., Waters, A. V., Padathara-Mathew, R., Okereke, V., & Sharma, A. J. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128340 · Cited by 2

Emerging Non-Conventional Approaches in mRNA-LNP Formulation for Therapeutic Applications

Zhang, Y., Linaje-Ferrel, G., Angel, J. M. R., Banik, O., Banoth, E., Kamen, A., Yandrapalli, N., & Perumal, A. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050527 · Cited by 2

Respiratory pathogen epidemiology in the post-pandemic era: a multicenter retrospective study from Saudi Arabia

Alzahrani, A. J., Shahidy, S. M. E., Bizri, N. E., Fakhr, A. E., Sheikh, A. E., Mahmoud, A., Shamsi, M. S., Khalid, F., Meashi, H., Mohammed, H. A., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13645-4 · Cited by 2

The Impact of COVID-19 on the Cardiovascular Health of Emerging Adults Aged 18-25: Findings From a Scoping Review

Rezler, Z., Ko, E., Jin, E., Ishtiaq, M., Papaioannou, C., Kim, H., Hwang, K., Lin, Y.-H., Colautti, J., Davison, K., et al. (2022) · CJC Pediatric and Congenital Heart Disease · doi:10.1016/j.cjcpc.2022.11.005 · Cited by 2

Predictive factors of delayed viral clearance of asymptomatic Omicron-related COVID-19 screened positive in patients with cancer receiving active anticancer treatment

Lee, V. H.-F., Chan, S.-K., Tam, Y.-H., Chau, T., Chan, J. F., Chan, S., Ip, C.-Y., Choi, C., Ng, S. C. Y., & Yuen, K.-K. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.397 · Cited by 2

Impact of Vaccination and Nonpharmaceutical Interventions With Possible COVID-19 Viral Evolutions Using an Agent-Based Simulation

Lee, S., Zabinsky, Z. B., Wasserheit, J. N., Ross, J. M., Chen, S., & Liu, S. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100155 · Cited by 2

The association between COVID-19 vaccination and confirmed patients with hospitalization in Omicron era: A retrospective study

Chang, M.-H., & Liao, K. (2023) · Medicine · doi:10.1097/md.0000000000036777 · Cited by 2

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Roberts, T., Uwenedi, G., Bruton, R. K., McIlroy, G., Damery, S. L., Sylla, P., Logan, N. A., Scott, S., Lau, M., Elzaidi, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00940-5 · Cited by 2

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Alleva, D. G., Feitsma, E. A., Janssen, Y. F., Boersma, H. H., Lancaster, T. M., Sathiyaseelan, T., Murikipudi, S., Delpero, A. R., Scully, M. M., Ragupathy, R., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00830-2 · Cited by 2

Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients

Zheng, Z., Wu, H., Sun, X., Lu, Y., Song, Y., Luo, Y., Zhou, T., Feng, M., Wan, P., Zhu, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29543 · Cited by 2

What to do with the new molecular publics: the vernacularization of pathogen genomics and the future of infectious disease biosocialities

Molldrem, S. (2024) · BioSocieties · doi:10.1057/s41292-024-00326-1 · Cited by 3

Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19

Kang, C. K., Kim, Y.-J., Jo, H. J., Lee, C. M., Kim, N. J., Lee, C., Choe, P. G., Park, W. B., & Oh, M. (2024) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2024.011 · Cited by 2

SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity

Richardson, S. I., Mzindle, N. B., Motlou, T. P., Manamela, N. P., van der Mescht, M. A., Lambson, B. E., Everatt, J., Amoako, D. G., Balla, S. R., von Gottberg, A., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00678-24 · Cited by 3

Original Antigenic Sin on Antibody Response in SARS-CoV-2 Infection

Wang, M., Guo, H., Ju, B., & Zhang, Z. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000125 · Cited by 3

Comparative 60-day effectiveness of bivalent versus monovalent mRNA vaccines in Shelby County: a population-level analysis

Plaxco, A. P., Kmet, J. M., Smeltzer, M. P., Jiang, Y., Taylor, M., & Nolan, V. G. (2024) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355241278852 · Cited by 2

Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients

Tometten, I., Brandt, T., Schlotz, M., Stumpf, R., Landmann, S., Kantauskaitė, M., Lamberti, J., Hillebrandt, J., Müller, L., Kittel, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476294 · Cited by 2

Immunobiology and immunotherapy of COVID-19

Lundstrom, K. H. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.002 · Cited by 3

Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon

Benlarbi, M., Kenfack, D.-D., Dionne, K., Côté-Chenette, M., Beaudoin-Bussières, G., Bélanger, É., Ding, S., Hamadama, O. G., Ngoume, Y. F., Tauzin, A., et al. (2025) · Virology · doi:10.1016/j.virol.2025.110467 · Cited by 2

Intersecting SARS-CoV-2 spike mutations and global vaccine efficacy against COVID-19

Tokhanbigli, S., Ghaleh, S. S., Rahimian, K., Mahmanzar, M., Bayat, S., Ahangarzadeh, S., Moradi, B., Mahmanzar, R., Wang, Y., Oliver, B. G. G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1435873 · Cited by 4

Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19

Yang, X., Tang, X., Sun, Y., Xi, H., Peng, W., Lu, Y., Teng, W., Zang, Y., & Jiang, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543212 · Cited by 2

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients

Davidov, Y., Indenbaum, V., Mandelboim, M., Asraf, K., Gonen, T., Tsaraf, K., Cohen‐Ezra, O., Likhter, M., Nemet, I., Kliker, L., et al. (2023) · Viruses · doi:10.3390/v15010253 · Cited by 2

The future for COVID-19 vaccines: public health assessment and perspectives based on scientific evidence

Andreoni, M., Bonanni, P., Cossarizza, A., Gabutti, G., Gesualdo, F., Grignolio, A., Icardi, G., Lopalco, P., & Vitale, F. M. (2023) · Infezioni in Medicina · doi:10.53854/liim-3101-1 · Cited by 2

Flattening the Curve after the Initial Outbreak of Coronavirus Disease 2019: A Data-Driven Modeling Analysis for the Omicron Pandemic in China

Sun, J., Li, Y., Xiao, L., Shao, N., & Liu, M. (2023) · Vaccines · doi:10.3390/vaccines11051009 · Cited by 2

Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care

Rajsri, K. S., McRae, M. P., Christodoulides, N. J., Dapkins, I. P., Simmons, G. W., Matz, H. C., Dooley, H. M., Fenyö, D., & McDevitt, J. T. (2023) · Bioengineering · doi:10.3390/bioengineering10060670 · Cited by 2

Pandemic scientific data sharing recommendations: examining and re-imagining pre-print servers after the end of the world-wide emergency

Doron, S., & Branch‐Elliman, W. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2023.410 · Cited by 2

Analyzing real-world data to understand COVID-19 vaccination effects on hospitalization rates in patients with solid malignancies

Dimitrov, G., Argirova, R., & Valkov, T. (2023) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2023.2282141 · Cited by 2

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

Pitak‐Arnnop, P., Ngamskulrungroj, P., Mahanonda, N., Auychai, P., Frech, B., Shavlokhova, V., & Stoll, C. (2024) · Medicina · doi:10.3390/medicina60030385 · Cited by 2

Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial

Figueroa, A. L., Torres, D., Reyes-Acuna, C., Matherne, P. G., Yeakey, A. M., Deng, W., Xu, W., Sigal, Y., Chambers, G., Olsen, M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00501-2 · Cited by 2

Effectiveness of bivalent mRNA booster vaccination and previous infection in older adults during Omicron period: real-world evidence

España, P. P., Castillo-Sintes, I., Legarreta, M. J., Bilbao‐González, A., Larrea, N., Gascón, M., Uranga, A., Artaraz, A., García-Asensio, J., Quintana, J. M., et al. (2024) · Age and Ageing · doi:10.1093/ageing/afae251 · Cited by 2

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

Vidian, V., Dikson, Litanto, V., Christy, S. N. A., & Jo, J. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00084 · Cited by 2

Which COVID boosters to take and when: a guide for the perplexed

Ledford, H. K. (2022) · Nature · doi:10.1038/d41586-022-02221-w · Cited by 2

Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort studyPreprint

Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · medRxiv · doi:10.1101/2023.01.21.23284855 · Cited by 2

Immune response to COVID-19 vaccines in people with immunodeficienciesPreprint

Ricotta, E., Zendt, M., Castillo, F. B., Kelly, S., Saturday, T. A., DeGrange, M., Ginigeme, A., Wu, L., Callier, V., Ortega‐Villa, A. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2514984/v1 · Cited by 2

SARS-CoV-2 RBD dimers elicit response comparable to VLPs in micePreprint

Love, J. C., Rodriguez‐Aponte, S. A., Tostanoski, L. H., Dalvie, N. C., Johnston, R. S., Jacob-Dolan, C., Powers, O. C., Hachmann, N. P., Miller, J. J., Hall, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2692315/v1 · Cited by 2

Patterns in Repeat Reinfections: Pre and Post Omicron EmergencePreprint

Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2023) · medRxiv · doi:10.1101/2023.06.29.23292041 · Cited by 2

How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effortPreprint

Wegner, F., Gil, B. C., Araud, T., Beckmann, C., Beerenwinkel, N., Bertelli, C., Carrara, M., Cerutti, L., Chen, C., Cordey, S., et al. (2023) · medRxiv · doi:10.1101/2023.08.28.23294715 · Cited by 2

Recapitulating memory B cell responses in a Lymphoid Organ-Chip to evaluate mRNA vaccine boosting strategiesPreprint

Jeger‐Madiot, R., Planas, D., Staropoli, I., Kervevan, J., Mary, H., Collina, C., Fonseca, B. F., Debarnot, H., Robinot, R., Gellenoncourt, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.02.578553 · Cited by 2

A 10-valent composite mRNA vaccine against both influenza and COVID-19Preprint

Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Cheng, N., Feng, P., Guan, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.05.583547 · Cited by 2

Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Preprint

Torresi, J., Earnest, L., Fernandez‐Ruiz, D., Edeling, M. A., Montoya, J., Yap, A. H. Y., Wong, C. Y., Holz, L. E., Gras, S., Collett, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4503306/v1 · Cited by 2

Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoproteinPreprint

Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.625234 · Cited by 2

Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 Pandemic

Friedman, S. M., Li, J., Thomas, P., Gurumurthy, M., Siderits, R. H., Nepomich, A., & Lifshitz, E. I. (2022) · Journal of Community Health · doi:10.1007/s10900-022-01142-z · Cited by 1

Who decides? Consent for healthcare decisions of minors in the United States

Stettner, N. M., Lavelle, E. N., & Cafferty, P. W. (2023) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001218 · Cited by 1

Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China

Duan, Y., Jiang, M., Suo, L., Xu, M., Li, X., Wang, Q., Bai, C., Wu, J., Zheng, X., Yang, W., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2289250 · Cited by 2

Adverse events following immunization of mRNA-1273 (Moderna) booster vaccine in clerkship students

Hendarto, H., Akbar, F. N., Nasir, N. M., Wulandari, E., & Adlani, H. (2024) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v13i2.23701 · Cited by 1

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters

Girard, B., Baum, E., Best, R. L., Campbell, T., Coupart, J., Dangerfield, K., Dhal, A., Jhatro, M., Martinez, B., Reifert, J. R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1285278 · Cited by 1

Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants

Zhang, J., Xu, Y., Chen, M., Wang, S., Lin, G., Huang, Y., Yang, C. J., Yang, Y., & Song, Y. (2024) · Angewandte Chemie · doi:10.1002/ange.202412294 · Cited by 1

The development of therapeutics and vaccines against COVID-19.

Zhao, T., Wang, Z., Tong, M., & Fei, Y. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116643 · Cited by 1

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice

Hurst, J. R., Naghibosadat, M., Budowski, P., Li, J., Samaan, P., Budiman, F., Kurtesi, A., Qi, F., Menon, H., Krishnan, R. G., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314061 · Cited by 1

Electrochemical pan-variant detection of SARS-CoV-2 through host cell receptor-mimicking molecular recognition

Lee, M., Kwon, J., Kim, H. B., Woo, S., & Oh, S. S. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117311 · Cited by 1

Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial

Liu, X., Qi, Y., Huang, T., Huang, L., Zhao, M.-X., Wang, Z., Dai, J., Wang, Y., Chen, J., Yang, X., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2502250 · Cited by 1

Characterization of the Binding and Inhibition Mechanisms of a Novel Neutralizing Monoclonal Antibody Targeting the Stem Helix Region in the S2 Subunit of the Spike Protein of SARS-CoV-2

Tan, S. S. E., Tam, E.-H., Lai, K. M., Wu, Y., Xiao, T., & Tan, Y. (2025) · Vaccines · doi:10.3390/vaccines13070688 · Cited by 1

Six-month follow-up of antibody response to bivalent mRNA SARS-CoV-2 vaccine booster in healthcare workers

Fedele, G., Schiavoni, I., Trentini, F., Leone, P., Olivetta, E., Fiore, S., Martino, A. D., Abrignani, S., Bandera, A., Clerici, P., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127524 · Cited by 1

Interprotomer crosstalk in mosaic viral glycoprotein trimers provides insight into polyvalent immunogen co-assembly

Chen, C., Lovendahl, K. N., Overbaugh, J. M., & Lee, K. K. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013143 · Cited by 1

Optimizing the schedule of BNT162b2 COVID-19 against long COVID and associated quality of life losses

Kuodi, P., Shibli, H., Zayyad, H., Wertheim, O., Wiegler, K. B., Jabal, K. A., Dror, A. A., Nazzal, S., Glikman, D., Charlett, A., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01160-7 · Cited by 2

Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents

Breznik, J. A., Ang, J. C., Bhakta, H., Liu, L.-M., Bilaver, L., Kennedy, A. E., Cowbrough, B., Rahim, A., Clare, R., Bramson, J. L., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128160 · Cited by 1

Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry

Madni, S. A., Olson, C. K., Zauche, L. H., Machefsky, A. M., Waters, A. V., Padathara-Mathew, R., Okereke, V., & Sharma, A. J. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128461 · Cited by 1

Nanoscale Spatial Engineering of Ligands Using DNA Origami for Precise Modulation of Membrane Receptor Signaling

Zhang, C. J., Fan, J., Guo, Y., Xiao, F., Chao, J., & Yang, D. (2026) · Angewandte Chemie · doi:10.1002/ange.2621334 · Cited by 1

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

Dagan, N., & Barda, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.08.017 · Cited by 1

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1873

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 9

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bula, M., Kalra, P. A., Dargan, P. I., Clark, R., Boffito, M., Sheridan, R., Bethune, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad500.1984 · Cited by 1

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 72